A novel therapeutic technology of specific RNA inhibition for acute promyelocytic leukemia: Improved design of maxizymes against PML/RARα mRNA

  • Authors:
    • H. Suwanai
    • H. Matsushita
    • H. Kobayashi
    • Y. Ikeda
    • M. Kizaki
  • View Affiliations

  • Published online on: January 1, 2002     https://doi.org/10.3892/ijo.20.1.127
  • Pages: 127-130
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Targeting of PML/RARα using a loss of function strategy in acute promyelocytic leukemia (APL) is a direct therapeutic approach for patients and may be the basis of future gene therapy for this leukemia. To achieve this, we designed specific maxizymes, novel allosterically controllable ribozymes, against both short and long PML/RARα isoforms. The maxizyme has sensor arms that can only recognize target sequences, and it can form a cavity that captures catalytically indispensable Mg2+. We deleted 1 base nucleotide in the Mg2+-binding pocket designed MzPRT50 and MzPRK55. The distance from the PML/RARα junction site to the center of effectors is only 2 bases, and there are 8 and 9 complementary bases in their inactive forms, respectively. Both maxizymes specifically cleaved PML/RARα mRNA but not wild-type RARα mRNA in a cell-free system. Modification of the sequence of the Mg2+-binding pocket will be important in designing the sequence-specific maxizymes against oncogenic genes.

Related Articles

Journal Cover

January 2002
Volume 20 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Suwanai, H., Matsushita, H., Kobayashi, H., Ikeda, Y., & Kizaki, M. (2002). A novel therapeutic technology of specific RNA inhibition for acute promyelocytic leukemia: Improved design of maxizymes against PML/RARα mRNA. International Journal of Oncology, 20, 127-130. https://doi.org/10.3892/ijo.20.1.127
MLA
Suwanai, H., Matsushita, H., Kobayashi, H., Ikeda, Y., Kizaki, M."A novel therapeutic technology of specific RNA inhibition for acute promyelocytic leukemia: Improved design of maxizymes against PML/RARα mRNA". International Journal of Oncology 20.1 (2002): 127-130.
Chicago
Suwanai, H., Matsushita, H., Kobayashi, H., Ikeda, Y., Kizaki, M."A novel therapeutic technology of specific RNA inhibition for acute promyelocytic leukemia: Improved design of maxizymes against PML/RARα mRNA". International Journal of Oncology 20, no. 1 (2002): 127-130. https://doi.org/10.3892/ijo.20.1.127